Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LUPRON DEPOT

« Back to Dashboard

Lupron Depot is a drug marketed by Abbvie Endocrine Inc and is included in five NDAs. It is available from one supplier. There are six patents protecting this drug.

The generic ingredient in LUPRON DEPOT is leuprolide acetate. There are eighteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

Summary for Tradename: LUPRON DEPOT

Suppliers: see list1

Clinical Trials for: LUPRON DEPOT

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
Status: Completed Condition: Precocious; Leuprolide Acetate; Luteinizing Hormone (LH); Gonadotrophin-releasing Hormone Agonist (GnRHa); Tanner Staging; Depot Formulation; Suppression of LH; Central Precocious Puberty (CPP); Gonadotrophin-releasing Hormone (GnRH); Lupron; GnRH Analog; Pediatrics Central Precocious Puberty

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
Status: Completed Condition: Puberty, Precocious

A Study of Leuprolide to Treat Prostate Cancer
Status: Completed Condition: Prostate Cancer

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
Status: Active, not recruiting Condition: Endometriosis; Dysmenorrhea; Dyspareunia

Melanoma Vaccine With Peptides and Leuprolide
Status: Completed Condition: Melanoma

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer

Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Status: Recruiting Condition: Myelodysplastic Syndrome RAEB 2; Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome RAEB 1

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
Status: Completed Condition: Breast Cancer

Study of Lupron Depot In The Treatment of Central Precocious Puberty
Status: Completed Condition: Puberty, Precocious

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Endocrine Inc
leuprolide acetate
INJECTABLE;INJECTION020517Jun 17, 2011RXNo<disabled><disabled>
Abbvie Endocrine Inc
leuprolide acetate
INJECTABLE;INJECTION020517Dec 22, 1995RXYes6,036,976<disabled><disabled>
Abbvie Endocrine Inc
leuprolide acetate
INJECTABLE;INJECTION019732Jan 26, 1989RXYes5,575,987<disabled><disabled>
Abbvie Endocrine Inc
leuprolide acetate
INJECTABLE;INJECTION020517Jun 17, 2011RXNo6,036,976<disabled>Y<disabled>
Abbvie Endocrine Inc
leuprolide acetate
INJECTABLE;INJECTION020011Oct 22, 1990DISCNNo5,575,987<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: LUPRON DEPOT

Expiration due to failure to pay maintenance fee
Patent Number:5,631,021 Tradename:
Expiration Date:May 20, 2005
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:
Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn